

IN THE SPECIFICATION:

Please amend the specification without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Page 1, line 1, please insert the following:

--This application is a divisional of prior application Serial No. 09/232,278, filed January 16, 1999 which is a continuation-in-part of copending International Application PCT/FR97/01315 having an international filing date of 15 July 1997, and designating the U.S. and claiming priority from French Application No. 96/09337, filed 19 July 1996. Reference is also made to the applications of Audonnet et al., Serial Nos 09/232,468, 09/232,477, 09/232,279, 09/232,479, and 09/232,478 and to the application of Rijsewijk et al. Serial No. 09/232,469, all filed July 19, 1996. All of the above-mentioned applications, as well as all documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference. Vectors of vaccines or immunological compositions of the aforementioned applications, as well as of documents cited herein or documents referenced or cited in documents cited herein or portions of such vectors (e.g., one or more or all of regulatory sequences such as DNA for promoter, leader for secretion, terminator), may to the extent practicable with respect to the preferred host of this application, also be employed in the practice of this invention; and, DNA for vectors of vaccines or immunological compositions herein can be obtained from available sources and knowledge in the art, e.g., GeneBank, such that from this disclosure, no undue experimentation is required to make or use such vectors.--

Page 1, line <sup>38</sup>~~37~~, please insert: --(See also U.S. Patent Nos. 5,846,946, 5,620,896, 5,643,578, 5,580,589, 5,589,466, 5,693,622, and 5,703,055; Science, 259:1745-49, 1993; Robinson et al., seminars in IMMUNOLOGY, 9:271-83, 1997; Luke et al., J. Infect. Dis. 175(1):91-97, 1997; Norman et al., Vaccine, 15(8):801-803, 1997; Bourne et al., The Journal of Infectious Disease, 173:800-7, 1996; and, note that generally a plasmid for a vaccine or immunological composition can comprise DNA encoding an antigen operatively linked to regulatory sequences which control expression or expression and secretion of the antigen from a host cell, e.g., a mammalian cell; for instance, from upstream to downstream, DNA for a

AR  
2/2/09

promoter, DNA for a eukaryotic leader peptide for secretion, DNA for the antigen, and DNA encoding a terminator.)--

Page 1, line 6, please amend as follows: --Associations of vaccines against certain feline viruses have already been proposed in the past.--

Page 2, line <sup>1</sup>~~2~~, please amend as follows: --The invention therefore proposes to provide a multivalent vaccine formula which makes it possible to ensure vaccination against a number of feline pathogenic viruses.--

AA  
2/2/09

Page 7, line 23, please amend as follows: --Brief Description of the Drawings --.

Immediately after page 20 and before the first page of claims (page 21), if appropriate, please insert the enclosed pages identified as --Sequence Listing.--

Please accept the enclosed paper copy of the sequence listing (identical to the sequence listing submitted for parent application Serial No. 09/232,278), the required Statements under 37 C.F.R. § 1.821(f) and (g).

**IN THE ABSTRACT:**

Please insert the Abstract as attached hereto.

**IN THE CLAIMS:**

Please cancel claims 1-10 and add new claims 11-25 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

--11. An immunogenic composition for inducing in a feline host an immunological response against feline immunodeficiency virus comprising at least one plasmid that contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus env protein, or gag protein, or pro protein, or gag and pro proteins, or env and gag and pro proteins.

12. The immunogenic composition according to claim 11 which comprises a plasmid that contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus env and gag and pro proteins.